malignant lymphoma cancer.
Conditions
Interventions
Palonosetron: day1 0.75mg (i.v.)
Sponsors
Hematology, Department of Medicine Kitasato University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who receive CHOP or R-CHOP therapy for malignant lymphoma cancer patients 2)No prior chemotherapy 3) Aged 20 years or older 4) Adequate organ function 5) ECOG performance status of 0 or 2 6) Written informed consent
Exclusion criteria
Exclusion criteria: 1) With other sever diseases 2) Clinical suspicion or history of metastasis to brain or meninges 3) Patients who need anticonvulsants therapy 4) Ascites and/or pleural effusion to need treatment 5) Pyloric stenosis and/or intestinal obstruction 6) Vomiting, or grade 2 or higher nausea according to CTCAE ver4.0 7) History of drug allergy 8) Pregnant or lactating women or women of childbearing potential, and no birth-control 9) Patient who doesn't have ability or intention that cooperates for procedure of the study 10) Not appropriate for the study at the physician's assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Response Rate in overall phase(0-120 hours after chemotherapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Response Rate in acute and delayed phase Complete Control Rate in overall, acute and delayed phase The proportion of patients without nausea in overall, acute and delayed phase Safety | — |
Countries
Japan
Contacts
Public ContactHirotoshi Kamata
Department of Medicine Kitasato University, School of Medicine Hematology
Outcome results
None listed